^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (clinicaltrials.gov)
    P1/2, N=768, Recruiting, Boehringer Ingelheim | N=582 --> 768 | Trial completion date: Sep 2029 --> Jan 2029 | Trial primary completion date: Sep 2029 --> Jan 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii) • Hernexeos (zongertinib)
    3d
    Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    3d
    CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov)
    P3, N=132, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    3d
    First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=155, Recruiting, Plexium, Inc.
    New P1 trial • First-in-human
    4d
    Semiquantitative immunohistochemical (IHC) pixelwise H-score of mitochondrial transcription factor A (TFAM) in gastric adenocarcinoma (GAC): clinicopathological significance and association with p53 and HER2. (PubMed, World J Surg Oncol)
    ROC and multi-variate Cox regression identified low TFAM expression as an independent poor prognostic variable for operable GAC patients, implying its potential as a quantitative prognostic biomarker. The observed associations with p53 and HER2 are hypothesis-generating and they require further validation to clarify TFAM's role in Warburg effect and GAC progression.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TFAM (Transcription Factor A, Mitochondrial)
    |
    HER-2 expression
    4d
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    4d
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    sigvotatug vedotin (PF-08046047)
    4d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Yale University
    New P2 trial • Circulating tumor DNA
    7d
    LB1908-1001: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    LB1908
    7d
    A nyelőcső-, GEJ- és gyomordaganatok immunterápiája. (PubMed, Magy Onkol)
    In esophageal tumors, adjuvant nivolumab is used. Among HER2-positive patients, adding pembrolizumab to trastuzumab and chemotherapy - in PDL1 CPS ≥1 cases - has become a new standard. A special mention must be made of MSI-H tumors, in which immunotherapy is highly effective, and adjuvant chemotherapy is not recommended according to current guidelines.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
    |
    HER-2 positive • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab)
    8d
    Immunohistochemical quantification of inflammation associated with gastric adenocarcinomas. (PubMed, Rom J Morphol Embryol)
    In the case of GAC with associated histological aggressiveness parameters, we found higher values of CD20 and CD68 reactions at the intratumoral level, and of CD45RO peritumorally, which suggests different immune immunophenotypes not only in relation to the tumor type, grade and stage, but also to the two compartments. These observations may be useful for establishing criteria for approaching and interfering with immune mechanisms in gastric carcinogenesis, which may improve patient prognosis.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD68 (CD68 Molecule)
    8d
    HX19 Robert J. Gorlin: a man for all syndromes. (PubMed, Br J Dermatol)
    As Professor Sydney Gellis remarked, 'When he gets down to the ovaries, he's gone about as far as he can go', capturing Gorlin's expansive curiosity and expertise. As well as the legacy of the syndromes he has been associated with, he has left a blueprint for all clinical colleagues to take forward in their daily practice - empathy, humour and generosity of spirit.
    Journal
    |
    PTCH1 (Patched 1) • SUFU (SUFU Negative Regulator Of Hedgehog Signaling)